Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular …
…, C Aubé, F Oberti, O Couturier, I Brenot-Rossi… - The Lancet …, 2017 - thelancet.com
Background Sorafenib is the recommended treatment for patients with advanced hepatocellular
carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective …
carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective …
Actualisation des recommandations de bonne pratique clinique pour l'utilisation de la TEP en cancérologie
…, A Tabarin, A Girard, JF Grellier, I Brenot-Rossi… - Bulletin Du Cancer, 2019 - Elsevier
La tomographie par émission de positons (TEP) est une technique d’imagerie fonctionnelle
de médecine nucléaire ayant fait la preuve de son intérêt clinique principalement en …
de médecine nucléaire ayant fait la preuve de son intérêt clinique principalement en …
The sentinel node procedure in breast cancer: nuclear medicine as the starting point
E Hindié, D Groheux, I Brenot-Rossi… - Journal of Nuclear …, 2011 - Soc Nuclear Med
Axillary node status is a major prognostic factor in early breast cancer. Staging with sentinel
node biopsy (SNB) leads to a substantial reduction in surgical morbidity. Recent …
node biopsy (SNB) leads to a substantial reduction in surgical morbidity. Recent …
[HTML][HTML] Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory …
R Devillier, D Coso, L Castagna, IB Rossi… - …, 2012 - ncbi.nlm.nih.gov
Background High-dose chemotherapy followed by autologous stem cell transplantation is
the standard treatment for relapsed and/or refractory Hodgkin’s lymphoma although half of …
the standard treatment for relapsed and/or refractory Hodgkin’s lymphoma although half of …
Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer?
I Brenot-Rossi, G Houvenaeghel… - Journal of Nuclear …, 2003 - Soc Nuclear Med
The aim of this study was to define the factors associated with nonvisualization of a sentinel
node (SN) in the axilla area during preoperative lymphoscintigraphy. Methods: We …
node (SN) in the axilla area during preoperative lymphoscintigraphy. Methods: We …
Value of 99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies
J Pasquier, BF Michel, I Brenot-Rossi… - European journal of …, 2002 - Springer
Despite improved diagnostic accuracy, differentiation of dementia with Lewy bodies (DLB)
and Alzheimer's disease (AD) on the basis of clinical findings remains problematic. The …
and Alzheimer's disease (AD) on the basis of clinical findings remains problematic. The …
Good clinical practice recommendations for the use of PET/CT in oncology
…, A Tabarin, A Girard, JF Grellier, I Brenot-Rossi… - European Journal of …, 2020 - Springer
Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine
functional imaging technique with proven clinical value in oncology. PET/CT indications are …
functional imaging technique with proven clinical value in oncology. PET/CT indications are …
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma
…, S Duran, B Chetaille, I Brenot‐Rossi… - Hematological …, 2014 - Wiley Online Library
Patients with relapsed or refractory Hodgkin lymphoma (RR‐HL) have poor outcomes.
Brentuximab vedotin (BV), an antibody–drug conjugate comprising an anti‐CD30 antibody …
Brentuximab vedotin (BV), an antibody–drug conjugate comprising an anti‐CD30 antibody …
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)
…, MA Mahé, P Gomez, I Brenot-Rossi… - European journal of …, 2014 - Springer
Purpose To assess prospectively the prognostic value of FDG PET/CT during curative-intent
radiotherapy (RT) with or without concomitant chemotherapy in patients with non-small-cell …
radiotherapy (RT) with or without concomitant chemotherapy in patients with non-small-cell …
[HTML][HTML] Hyperprogressive disease in anorectal melanoma treated by PD-1 inhibitors
…, P Rochigneux, D Olive, S Taix, I Brenot-Rossi… - Frontiers in …, 2018 - frontiersin.org
The 5-year survival rate of primary anorectal malignant melanoma is less than 20%. Optimal
treatment of this condition remains controversial regarding locally disease, and whether any …
treatment of this condition remains controversial regarding locally disease, and whether any …